PT-141 vs Vyleesi: Comparing the Indexed Record
Before PT-141 and Vyleesi can be compared on anything else, they have to be compared on evidence: what has actually been indexed, and where.
Side-by-side research profile
| Parameter | PT-141 | Vyleesi |
|---|---|---|
| PubMed indexed records | 21 | 9 |
| Registered studies (ClinicalTrials.gov) | 4 | 1 |
| Literature depth | Emerging | Emerging |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Compound profiles
PT-141 in the indexed record
PT-141 returns 21 indexed records on PubMed, a limited record, alongside 4 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Curr Opin Investig Drugs, Int J Mol Sci, J Sex Med, spanning 2004–2026.
- Bremelanotide — , 2006. PMID: 31369224
- PT-141 Palatin — Curr Opin Investig Drugs, 2004. PMID: 15134289
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives — Int J Mol Sci, 2026. PMID: 42123471
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist — J Sex Med, 2006. PMID: 16839319
Vyleesi in the indexed record
The literature on Vyleesi is a limited body of work: 9 PubMed-indexed records, alongside 1 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Ann Pharmacother, Drugs, Med Lett Drugs Ther, spanning 2006–2020.
- Bremelanotide (Vyleesi) for hypoactive sexual desire disorder — Med Lett Drugs Ther, 2019. PMID: 31381550
- Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder — Ann Pharmacother, 2020. PMID: 31893927
- Bremelanotide: First Approval — Drugs, 2019. PMID: 31429064
- Bremelanotide — , 2006. PMID: 31369224
How the literature differs
The indexed record is not symmetrical between these two compounds. PT-141 carries 12 more indexed records than Vyleesi, which means published methodology, characterisation data and replication attempts are more readily located for PT-141. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (4 vs 1) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Classification and why it matters
PT-141 and Vyleesi sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for PT-141 describes conditions validated for PT-141: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Vyleesi without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Selecting between them for a study design
PT-141 and Vyleesi are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (PT-141) generally offers more methodological precedent.
What the paperwork has to show
A certificate of analysis is only meaningful when it names the lot printed on the vial. Purity by HPLC and identity by mass spectrometry answer two different questions, and a document reporting one is not evidence of the other.
Frequently asked questions
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Are PT-141 and Vyleesi the same compound?
No. They are structurally distinct research compounds with separate literature records — 21 indexed records for PT-141 and 9 for Vyleesi.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Which of PT-141 or Vyleesi has more published research?
PT-141, with 21 indexed PubMed records against 9.
Related references
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.